Related Experiment Video
Updated: Jul 5, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Thomas Berg1, Giampiero Carosi
1Charite Universitatsmedizin Berlin, Berlin, Germany. thomas.berg@charite.de
Antiviral Therapy
|April 25, 2008
Summary
Rapid virological response (RVR) at week 4 predicts sustained virological response (SVR) in hepatitis C virus (HCV) genotypes 2 or 3. RVR can guide shorter treatment durations, while non-RVR may benefit from intensified therapy.
Area of Science:
- Hepatology
- Virology
- Clinical Pharmacology
Background:
- Hepatitis C virus (HCV) genotypes 2 and 3 require optimized treatment strategies.
- Early virological response (EVR) is not a reliable predictor of treatment success in these genotypes.
- Rapid virological response (RVR) at week 4 is a strong predictor of sustained virological response (SVR).
Purpose of the Study:
- To evaluate the utility of RVR in predicting SVR for HCV genotypes 2 and 3.
- To assess the efficacy of abbreviated treatment durations based on RVR status.
- To explore intensified therapy options for patients not achieving RVR.
Main Methods:
- Review of published studies on shortened treatment durations for HCV genotypes 2 and 3.
- Analysis of data from the ACCELERATE trial, a large randomized study of abbreviated HCV therapy.
- Comparison of treatment outcomes based on RVR achievement and baseline viral load.
Main Results:
- RVR is a significant predictor of SVR in patients with HCV genotypes 2 and 3.
- Patients achieving RVR, especially with low baseline viral load, may be candidates for shorter treatment.
- Non-RVR patients may benefit from intensified treatment regimens (longer duration or higher doses).
Conclusions:
- Response-guided therapy, utilizing RVR, can optimize treatment for HCV genotypes 2 and 3.
- Balancing the benefits of abbreviated therapy against increased relapse rates is crucial.
- Individualized treatment strategies are key to maximizing SVR rates without compromising outcomes.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...